Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
AJ,
Like you said this is getting fun. I love all the re-kindled excitement as court dates are scheduled and CommScopes involvement in the Chanbond case is unfolding right before our eye. Definitely exciting!!!
Long UOIP,
~Magnus
There is a PDF linked to the "The Life of an Appeal" provided by the United States Court of Appeals for the Federal Circuit.
Since this case has been scheduled for oral argument on August 6, 2019 at 10:00 a.m. It corresponds with the 5th step or stage in the life of an appeal.
Hope that makes sense
Long UOIP,
~Magnus
Cisco appeal is at stage 5 WOOT! WOOT!
http://www.cafc.uscourts.gov/sites/default/files/rules-of-practice/notices/Life_of_an_Appeal_Narrative_and_flowchart.pdf
Thank you dillythekid for finding the pacer.
UNITED STATES COURT OF APPEALS
FOR THE FEDERAL CIRCUIT
717 MADISON PLACE, N.W.
WASHINGTON, D.C. 20439
PETER R. MARKSTEINER CLERK'S OFFICE
CLERK OF COURT 202-275-8000
18-1886 - ChanBond, LLC v. Cisco Systems, Inc.
NOTICE OF ORAL ARGUMENT
https://drive.google.com/file/d/1-xNELgceOGXLg9CARuwUYM20Wtl3ShJY/view
Long UOIP,
~Magnus
I cannot speak for LAHO, I only post what I find.
However, it’s my opinion that Benito Novas is a marketing genius.
Long LAHO,
Magnus
Global Stem Cells Group to Host Argentina Lectures on Newest Stem Cells Therapies.
Two ISSCA experts will be featured in Santiago del Estero on October 5th as part of the group’s non-profit mission to bring stem cells therapies to global communities
Miami Lakes, Florida (PRUnderground) June 26th, 2019
The International Society for Stem Cell Application (ISSCA), a multi-disciplinary community of scientists and physicians collaborating to treat diseases and lessen human suffering through science, technology, and regenerative medicine, will be visiting Argentina to host two lectures on the newest stem cells therapies. The event will be held in Santiago del Estero on October 5, 2019 and will feature global experts in the industry who will offer their expertise and engage the audience in question and answer sessions.
ISSCA will be hosting Dra. Silvina Pastrana and Dr. Walter Soler in a magistral conference as part of its non-profit activities and its commitment to sharing knowledge of stem cells therapies and regenerative medicine with doctors across the world, especially those in developing global regions where stem cells practices and knowledge are in their infancy.
Dra. Silvina Pastrana of Argentina, who currently serves as the medical director of the Stem Cells Center in Buenos Aires and as an advisory board member of the Global Stem Cells Group, will present a lecture entitled “Stem Cells Therapies Fundamentals: How Stem Cells Can Help Your Patients.” Additionally, Dr. Walter Soler of Argentina will present a lecture entitled “A Testimonial Case of Reinnervation of Free Areola Grafts in Trans-Masculine Patients,” informed by his over 150 successful procedures in the field. Dr. Soler is a graduate of Pontificia Universidad Católica de Córdoba of Argentina.
“We are grateful that Dra. Andrea Lepaire has invited us to participate in the Estetica y Salud medical congress, so we can bring the latest groundbreaking stem cells therapies to doctors in Argentina,” said Benito Novas, CEO of the Global Stem Cells Group. “This event is the first of its kind for doctors in the northern part of Argentina, giving them critical access to industry experts from whom they can receive in-person instruction and information on the latest advancements in our field.”
To learn more about ISSCA and all of their upcoming and past events, visit https://issca.us/.
About International Society for Stem Cells Applications
The International Society for Stem Cells Applications (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology, and the practice of regenerative medicine. Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.
ISSCA bridges the gaps between scientists and practitioners in Regenerative Medicine. Their code of ethics emphasizes principles of morals and ethical conducts.
At ISSCA, their vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification. ISSCA serves its members through advancements made to the specialty of regenerative medicine. They aim to encourage more physicians to practice regenerative
medicine and make it available to benefit patients both nationally and globally.
For more information, please visit https://www.issca.us/ or send an email to info@stemcellsgroup.com
Long LAHO,
Magnus
Stem Cells Group to Host Regenerative Medicine Symposium at the University of Miami
https://www.prunderground.com/stem-cells-group-to-host-regenerative-medicine-symposium-at-the-university-of-miami/00159264/
Stem Cells Group to Host Regenerative Medicine Symposium at the University of Miami
Industry: Healthcare
ISSCA will partner with SIISDET at the October 2019 event, which will share valuable information with physicians regarding recent breakthroughs in regenerative medicine
Miami Lakes, FL (PRUnderground) June 26th, 2019
The International Society for Stem Cells Application (ISSCA), a multi-disciplinary community of scientists and physicians collaborating to treat diseases and lessen human suffering through science, technology, and regenerative medicine, will co-host a symposium in October 2019 with the Sociedad Internacional en Investigación, Salud, Desarrollo Empresarial (SIISDET). The event will be held at the University of Miami on October 22-24, 2019 in the West Ballroom of the Shalala Student Complex.
The Miami symposium will feature educational sessions and product information and demonstrations aimed at doctors looking to incorporate regenerative medicine into their practices. Industry experts will be on hand to share the latest information on the newest compounds in the allogeneic stem cells market, including exosomes, amniotic fluid compounds, and cord blood products.
Allogeneic compounds have gained growing popularity in regenerative medicine due to their increased safety and treatment efficacy. With this in mind, ISSCA representatives will be on hand to give physicians the opportunity to learn more about these popular treatment solutions and how they can be utilized in their practices.
“We are pleased to be able to partner with SIISDET to be able to offer this exciting symposium at the University of Miami,” said Benito Novas, CEO of ISSCA. “We are continually seeking ways to bring the latest advances in regenerative medicine to physicians across the globe. Our Miami symposium will play a critical role in accomplishing this by helping physicians expand their knowledge bases and explore new treatment options in regenerative medicine.”
In addition to educational sessions, the Miami symposium will provide networking and social opportunities for those in attendance. Events on the agenda include an optional boat trip around Miami on the Miami River and a Columbian Day celebration offering live music and Colombian cuisine to symposium attendees.
To learn more about ISSCA’s Miami symposium or to register for the event, visit https://www.issca.us/.
About International Society for Stem Cells Applications
The International Society for Stem Cells Applications (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology, and the practice of regenerative medicine. Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.
ISSCA bridges the gaps between scientists and practitioners in Regenerative Medicine. Their code of ethics emphasizes principles of morals and ethical conducts.
At ISSCA, their vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification. ISSCA serves its members through advancements made to the specialty of regenerative medicine. They aim to encourage more physicians to practice regenerative
medicine and make it available to benefit patients both nationally and globally.
For more information, please visit https://www.issca.us/ or send an email to info@stemcellsgroup.com
OTC Short Report
https://www.otcshortreport.com/company/LAHO
The average % of Vol Shorted for the past 21 days is 52.95571429 and it has been below average the past 7 days.
Long LAHO,
~Magnus
Do not get caught up in any confusion. Chanbond is a wholly owned subsidiary of UOIP, as evidenced very recently in Supreme Court filings.
Thanks Broke
Long UOIP,
~Magnus
Thank you so much Renee, that information has changed my entire thinking of UOIP. For over two years I have been wondering through the desert. But no longer, I will sell all of my shares in UOIP and hide my money in coffee cans.
Long UOIP,
Magnus
Treatment options across the GLOBE!!!!
The income potential is outstanding
Benito Novas is a marketing and networking guru.
Long LAHO,
Magnus
https://www.prunderground.com/issca-reaches-agreement-with-belgiums-churchill-aesthetic-center/00158843/
...”We look forward to ISSCA’s exciting new partnership with Belgium’s Churchill Aesthetic Center and the possibilities it brings in delivering safe and effective regenerative medicine treatment options to more patients across the globe,” said Benito Novas, CEO of the Global Stem Cells Group. “This partnership will help us prepare more physicians to deliver cutting edge treatment options to their patients that help alleviate suffering while also achieving our mission of expanding our global reach.”
To learn more about Churchill Aesthetic Center, visit https://www.churchill-aesthetic-center.be/.
To learn more about ISSCA, visit https://issca.us/.
About Global Stem Cells Group
Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.
Global Stem Cell Group aka Global Money Tree Group
“...The cutting-edge facility will be equipped by Adimarket, LLC, a subsidiary of the Global Stem Cells Group. Adimarket will outfit the center with equipment and supplies designed to not only teach doctors about the latest protocols in regenerative medicine but also to treat patients suffering from degenerative diseases and sports injuries...”
Long LAHO,
Magnus
S800 "Wonderful place to work"
Very supportive management, understanding and very cordial staff, make your own schedule, part time and full time hours, fast pace, days go by quickly The management is very caring and understanding. They really work as a team and this is the most professional job I have worked at. They treat their workers very good and are very considerate. I love this job and it is a very good place to work
https://www.glassdoor.com/Reviews/Employee-Review-Service-800-RVW24913601.htm
It's great to hear employees feel this way towards management. I feel good with my decision to invest in them.
Long BYOC,
~Magnus
Pacer ChanBond_LLC_v_Atlantic_Broadband_Group_LLC__dedce-15-00842__0414.0
http://s000.tinyupload.com/?file_id=59831761855979128454
Long UOIP,
~Magnus
Pacer ChanBond_LLC_v_Atlantic_Broadband_Group_LLC__dedce-15-00842__0427.0
http://s000.tinyupload.com/index.php?file_id=00907532241515594256
Long UOIP,
~Magnus
Pacer ChanBond_LLC_v_Atlantic_Broadband_Group_LLC__dedce-15-00842__0428.0
http://s000.tinyupload.com/?file_id=73510771559197577197
Long UOIP,
~Magnus
That’s an excellent point Nicasurf. Thank you for that perspective
Long LAHO,
Magnus
August 28th or September 12th, it’s good to hear they will have the financials current.
Long LAHO,
Magnus
“We are excited to join forces with Lans Holdings,” said Benito Novas, President and CEO of Global Stem Cells Group. “This union will allow us to have access to the capital markets to further fuel our growth as the global stem cells market enters into an accelerated expansion phase.”
http://www.stemcellsgroup.com/lans-holdings-enters-into-binding-loi-to-acquire-global-stem-cells-group/
Global Stem Cell Group has a goal to grow and assist more and more medical professionals to excel in stem cell therapies.
Benito Novas is a visionary!!!!!
Long LAHO,
Magnus
Lans Holdings is currently working to bring all of its financials current and expects this to be completed and filed with the SEC within the next 90 days.
This was stated in their press release from June 12, 2019. That would mean they plan to have the financials current by September 12, 2019
https://www.globenewswire.com/news-release/2019/06/12/1867610/0/en/LAHO-Global-Stem-Cells-Group-Announces-Opening-of-Two-New-Stem-Cell-Centers.html
Long LAHO,
Magnus
Press Releases
Dali Wireless Files Second Patent Infringement Lawsuit Against CommScope; Seeks Ban on OneCell and ION-E Products
February 22, 2019
Dali files suit against CommScope Technologies LLC and CommScope Holding Company, Inc. alleging infringement of U.S. Patents 10,045,314 and 10,080,178; seeking damages and an injunction to stop manufacturing, sale, and distribution of CommScope OneCell and ION-E products
Menlo Park, California – February 22, 2019 – Dali Wireless, Inc. today announced it has filed a lawsuit in the United States District Court for the District of Delaware against CommScope Technologies LLC and CommScope Holding Company, Inc., for infringement of U.S. Patent Numbers 10,045,314 and 10,080,178. Dali’s patents disclose and claim software defined radio systems that are building blocks for 4G/5G era in-building wireless networks. In its complaint, Dali alleges that CommScope incorporated Dali’s patents into its OneCell and ION-E products. Dali has petitioned the Court for monetary damages and an injunction preventing CommScope from making, using, or selling its OneCell and ION-E products.
This new lawsuit against CommScope is in addition to Dali’s previous assertion of two patents against CommScope Technologies LLC and CommScope Connectivity LLC, in counterclaims pending in the Northern District of Texas (case number 3:16-cv-477-M). In that case, Dali asserts U.S. Patent Nos. 9,031,521 and 9,531,473, which disclose and claim, among other things, power amplifier systems and methods of operation and software-configurable DAS, which are used in modern-day wireless transmission through digital radio distribution systems. Dali also asserted U.S. Patent No. 8,149,950, which discloses and claims efficient baseband predistortion linearization systems, but dismissed it from the case after Texas Instruments took a license to the patent.
Dali is a world-wide innovator in digital radio distribution systems and digital predistortion technology that revolutionized in-building and outdoor wireless coverage and capacity. Dali’s groundbreaking products have been consistently recognized by industry publications. For example, Dali has been recognized as a “Hot Tech Innovator” by ABI Research and was ranked No. 1 in innovation in an ABI Research report, “In-Building Wireless, DAS Vendor Competitive Assessment”.
Dali’s dedication to innovation has also resulted in it being granted over 400 global patents and pending patent applications. In addition to providing broad coverage on digital predistortion and radio frequency (“RF”) distribution technology, Dali’s patents are critically important to enabling 4G, 5G and virtual Radio Access Network (vRAN).
Want to see how much stem cell is trending. Use the trend report from Google.
https://trends.google.com/trends/explore?q=Stem%20cell&geo=US
Long LAHO,
Magnus
Stem cell therapy plays a substantial role in cancer treatments and now that the campaign promises for the 2020 presidency is to cure cancer, stem cell therapy is going to really grow in market capital
Long LAHO,
Magnus
$4.773 would be absolutely life changing
Long LAHO,
~Magnus
The stem cell market is growing and Global Stem Cell Group is an active force in this growth. GSCG's involvement in International Society for Stem Cell Application( ISSCA ) is a testament to their knowledge and dedication.
Long LAHO,
~Magnus
$17.3 Bn Stem Cell Banking Market - Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024
DUBLIN, March 22, 2019 /PRNewswire/ -- The "Stem Cell Banking Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024" report has been added to ResearchAndMarkets.com's offering.
The global stem cell banking market was worth US$ 8.1 Billion in 2018
Stem cell banking is one of the most promising as well as the fastest growing segment of the next-generation stem cell therapy. It is the process of extracting, freezing and storing stem cells for potential future use. Some of the sources through which stem cells are obtained include embryo, umbilical cord, cord blood, placenta and bone marrow.
These cells are used for treating a number of different diseases including diabetes, thalassemia, leukemia, sickle cell anemia and cardiac diseases. Moreover, they are also employed for generating platelets, red blood cells and white blood cells. The potential of stem cells to regenerate has led to their applications in tissue engineering, gene therapy and regenerative medicines.
Looking forward, we expect the global stem cell banking market to reach a value of US$ 17.3 Billion by 2024, exhibiting a CAGR of 13.5% during 2019-2024.
Global Stem Cell Banking Market Drivers:
While the average human life expectancy has increased owing to the advancements in medical science, human aging is still associated with several diseases. Thus, the elevating count of geriatric population will drive the demand for stem cell therapy in the coming years.
Regulatory authorities as well as non-governmental organizations (NGO), across both developed and emerging regions, are taking initiatives for instilling awareness amongst consumers about the therapeutic potentials of stem cells, thereby influencing the stem cell banking market growth.
Increasing fertility rates has led to a rise in the number of children across the globe. This offers lucrative opportunities for preserving the umbilical cord of infants which contains hematopoietic (blood) stem cells.
Some of the other factors which are catalyzing the growth of the market include escalating disposable incomes, increasing approval of clinical trials in stem cell research, growing prevalence of chronic diseases and technological advancements.
Product Type Insights:
On the basis of product types, the market has been segmented as adult stem cells, human embryonic cells and IPS cells. Presently, adult stem cells account for the majority of the market share as they help in repairing damaged tissues via cell division. In addition to this, adult stem cells offer advantages like ease of harvesting, high acceptance in the human body and effectiveness in tissue generation.
Service Type Insights:
Based on service types, the market has been segmented as sample preservation and storage; sample analysis; sample processing; and sample collection and transportation.
Bank Type Insights:
Based on the bank type, the market has been segregated as private and public stem cell banks. Private stem cell banks currently dominate the market, holding the largest share.
Utilization Insights:
Based on the utilization, the market has been segregated as used and unused.
Application Insights:
On the basis of application, the market has been segmented as personalized banking applications, research applications and clinical applications.
Regional Insights:
On a geographical front, North America enjoys the leading position in the global stem cell banking market on account of advancements in medical infrastructure and availability of federal funding for stem cell research. Other regions include Europe, Asia Pacific, Middle East and Africa, and Latin America.
The global stem cell market size is expected to reach USD 15.63 billion by 2025, at a CAGR of 8.8% during the forecast period
NEWS PROVIDED BY
Reportlinker
Apr 17, 2019, 18:16 ET
SHARE THIS ARTICLE
NEW YORK, April 17, 2019 /PRNewswire/ -- Stem Cell Market Size Analysis Report By Product (Adult, hESC, Induced Pluripotent), By Application (Regenerative Medicine, Drug Discovery & Development), By Technology, By Therapy, And Segment Forecasts, 2019 - 2025
Read the full report: https://www.reportlinker.com/p05768015/?utm_source=PRN
The global stem cell market size is expected to reach USD 15.63 billion by 2025, at a CAGR of 8.8% during the forecast period. Amplifying research studies targeted at widening the utility scope of stem cell products is anticipated to drive the growth. These research projects are set to offer new opportunities for implementation of several clinical applications of stem cells. Thus, extensive research on exploring varied applications of stem cells would impact treatment options that aid in disease-modification.
In addition, collaborations targeted at achieving robust manufacturing of high-quality differentiated cells is expected open up new avenues of market expansion over the forecast period.Rapid transition from conventional treatment methods to regenerative medicine has been observed over the past few years.
Regenerative medicine is set to become the new prototype of treatment in human health having the potential to address unmet medical needs across the globe. Integration of biologics, chemical compounds, materials, and devices is witnessed in stem cell therapeutics making it an interdisciplinary field.
Moreover, rising recognition of cellular therapies as an emerging revolutionary advancement has been witnessed in the healthcare industry in recent years.Business expansion is adopted by companies aiming at strengthening their portfolio regarding cellular therapy.
This is expected to improve detailed understanding and future potential of stem cells for the of patients suffering from Parkinson's disease, diabetes, injuries associated with spinal cord, and other neurodegenerative disorders.
Further, a maturing and strongly diversified clinical pipeline is expected to contribute to the growth of stem cell market. Availability of latest data during the mid and late stage of the regenerative medicine clinical trials and increase in the product approvals regarding the same is expected to drive the market.
Adult stem cells displayed highest contribution in the market and is expected to maintain its dominance over the forecast period.Factors such as minimal ethical issues, lower rejection rates, and long-term renewal property associated with stem cells utility has contributed to the dominance of this segment.
Moreover, the characteristic property of these cells to regenerate into malignant cells is anticipated to support the estimated share.
Scientists at Michigan State University revealed novel type of cells, named induced XEN cells, originated from a cellular trash pile in March 2016.The conclusions drawn from this research study is expected to drive emerging regenerative medicine treatment methods.
In January 2019, research professionals at the University of Freiburg carried out research on the potential of mesenchymal stems cells in repairing damaged organs. This is further anticipated to boost research as well as sales in the market throughout the study period.
Further key findings from the report suggest:
• Based on application regenerative medicine is estimated to hold a substantial market share in terms of revenue over the forecast period, owing to rise in emerging pipeline projects
• Progress of acquisition technology is expected to gain momentum during the forecast period owing to the rising research projects that demand the use of harvesting techniques
• Amongst the type of therapies used, autologous therapy accounted for the largest share of the stem cell market
• Likelihood of getting new infections is less in autologous cell-based therapy, consequently enhancing its adoption
• R&D activities carried out on large scale and huge funds granted by funding bodies to advance cellular research in U.S. have made North America the dominant region in the global market
• Vast research studies taking place in Singapore and Japan is anticipated to propel the Asia Pacific market in the forthcoming years
• Osiris Therapeutics Inc.; Celgene Corporation; BIOTIME, INC.; Cynata; Advanced Cell Technology Inc.; and STEMCELL Technologies Inc.; are some of the key market players
• The companies are undergoing strategic partnership to enhance their product line. They are keen on seeking investments from overseas organizations along with adopting partnership strategies with pharmaceutical organizations, which is set to fuel the market growth.
Snippet from walletinvestor.com for LAHO
Questions & Answers about Lans Holdings Projection
What is the Lans Holdings stock price / share price today?
The Lans Holdings stock price is 0.001 USD today.
Will Lans Holdings stock price grow / rise / go up?
Yes. The LAHO stock price can go up from 0.001 USD to 4.773 USD in one year.
Is it profitable to invest in Lans Holdings stock?
Yes. The long-term earning potential is +477231% in one year.
Will LAHO stock price fall / drop?
No
$4.773 would we out of this world!!!!
Long LAHO,
~Magnus
Snippet from walletinvestor.com
Questions & Answers about Beyond Commerce Projection
What is the Beyond Commerce stock price / share price today?
The Beyond Commerce stock price is 0.00370 USD today.
Will Beyond Commerce stock price grow / rise / go up?
Yes. The BYOC stock price can go up from 0.00370 USD to 0.0319 USD in one year.
Is it profitable to invest in Beyond Commerce stock?
Yes. The long-term earning potential is +763.23% in one year.
Will BYOC stock price fall / drop?
No
Long BYOC,
~Magnus
Thank you GM_FSJ
Long BYOC,
~Magnus
Nice volume today of 5,373,261 spread across 40 trades.
Long BYOC
~Magnus
Goodnight gumzsa
Maybe it's the Illuminati, The Circle, and or The Order
Long UOIP,
~Magnus
Adude, Can you post a few tidbits about what you searched and I will also look into this with you
Long UOIP,
~Magnus
How does MAXM fit into this? Do they own a percentage of BYOC and helping BYOC get their financials straight? Was MAXM the driving force to obtaining OCTQB?
Long BYOC,
~Magnus
Good Morning Gumza and everyone else excited about BYOC
Long BYOC,
~Magnus
Thank you for the updates, much appreciated
Long BYOC,
~Magnus
That is a practical look at this activity. Thank you Poker
~Magnus
Thank you and I will be watching for their report.
Long UOIP,
Magnus
Any word on the Supreme Court? On May 28,2019 DISTRIBUTED for Conference of 6/13/2019.
Long UOIP,
Magnus
What bait? Without running the numbers, many of use bought shares in the triple zeros. 1.6 billion shares minus 900 million shares that are Billy Carters, leaves 700 million shares a majority of which were purchased in the triple zeros. Wow they are really killing it by taking all the novices for there few hundred thousand dollars. But there are a heck of a lot of lawyers fees and Billy is the one holding the bag right now.
If Chanbond/UOIP is such the scam why has it stood the test of the so many courts and opposing lawyers.
Why post “Patent Troll” at every turn of events?
Long UOIP,
Magnus
Jump to the 3:00 minute mark for Cramer's thoughts on Arris and Commscope
https://www.cnbc.com/2019/06/13/cramers-lightning-round-ball-is-in-a-duopoly-it-is-a-total-windfall.html
Long UOIP,
~Magnus